We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+0.37%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$96.3M
AUM Growth
+$13.8M
Cap. Flow
+$23.6M
Cap. Flow %
24.48%
Top 10 Hldgs %
70.51%
Holding
39
New
12
Increased
8
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
APLT
Applied Therapeutics
APLT
+$2.82M
2
KGC icon
Kinross Gold
KGC
+$2.16M
3
WPM icon
Wheaton Precious Metals
WPM
+$2.05M
4
EQX icon
Equinox Gold
EQX
+$2.03M
5
SA
Seabridge Gold
SA
+$1.98M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$817K
2
ALT icon
Altimmune
ALT
+$614K

Sector Composition

Rank Sector Weight
1 Healthcare 66.32%
2 Materials 21.18%
3 Industrials 3.38%
4 Financials 1.16%
5 Consumer Staples 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDX icon
1
Aldeyra Therapeutics
ALDX
$91.7M
$20.3M 21.02%
3,031,915
+16,247
+0.5% +$121K
APLT
2
DELISTED
Applied Therapeutics
APLT
$12.9M 13.34%
5,162,088
+1,712,088
+50% +$2.82M
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$12.8M 13.24%
490,422
+40,000
+9% +$1.04M
AVDL
4
DELISTED
Avadel Pharmaceuticals
AVDL
$6.18M 6.42%
600,000
+100,000
+20% +$1.34M
HOOK
5
DELISTED
HOOKIPA Pharma
HOOK
$3.4M 3.53%
551,739
– –
VRNA
6
DELISTED
Verona Pharma
VRNA
$3.26M 3.38%
200,000
– –
SA
7
Seabridge Gold
SA
$2.8B
$2.6M 2.7%
246,597
+166,597
+208% +$1.98M
GDX icon
8
VanEck Gold Miners ETF
GDX
$23B
$2.47M 2.57%
91,850
– –
SIL icon
9
Global X Silver Miners ETF NEW
SIL
$4.08B
$2.14M 2.23%
89,700
– –
KGC icon
10
Kinross Gold
KGC
$28.5B
$2.01M 2.08%
+440,000
New +$2.16M
FNV icon
11
Franco-Nevada
FNV
$41.4B
$1.94M 2.01%
14,500
+7,500
+107% +$1.06M
WPM icon
12
Wheaton Precious Metals
WPM
$50.6B
$1.93M 2%
+47,500
New +$2.05M
AEM icon
13
Agnico Eagle Mines
AEM
$72.6B
$1.82M 1.89%
+40,000
New +$1.96M
SILV
14
DELISTED
SilverCrest Metals Inc. Common Shares
SILV
$1.81M 1.88%
410,000
+240,000
+141% +$1.22M
ENTX icon
15
Entera Bio
ENTX
$101M
$1.8M 1.87%
2,484,275
– –
EQX icon
16
Equinox Gold
EQX
$7.32B
$1.78M 1.85%
+420,929
New +$2.03M
GDXJ icon
17
VanEck Junior Gold Miners ETF
GDXJ
$7.06B
$1.71M 1.78%
53,150
– –
MAG
18
DELISTED
MAG Silver
MAG
$1.66M 1.72%
+160,000
New +$1.78M
BAH icon
19
Booz Allen Hamilton
BAH
$8.7B
$1.42M 1.47%
13,000
– –
AG icon
20
First Majestic Silver
AG
$8.05B
$1.41M 1.46%
+275,000
New +$1.63M
V icon
21
Visa
V
$677B
$1.12M 1.16%
4,850
– –
TMO icon
22
Thermo Fisher Scientific
TMO
$211B
$1.06M 1.1%
2,100
– –
CVS icon
23
CVS Health
CVS
$137B
$1.01M 1.05%
14,500
– –
MO icon
24
Altria Group
MO
$122B
$955K 0.99%
22,700
– –
NOC icon
25
Northrop Grumman
NOC
$77B
$953K 0.99%
2,165
– –
1
2

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Knoll Capital Management held 39 positions worth $96.3M, up 17% from $82.5M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Knoll Capital Management deployed $23.6M of net new capital in Q3 2023, opening 12 new positions and adding to 8 existing holdings. Its largest new stake was Kinross Gold: 440,000 shares worth $2.01M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 79% a quarter earlier, followed by Materials and Industrials.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $817K trimmed.

  • Knoll Capital Management's largest Q3 2023 buy was Kinross Gold: 440,000 shares worth $2.01M.
  • Knoll Capital Management added most to Applied Therapeutics in Q3 2023, an estimated $2.82M increase.
  • Knoll Capital Management's biggest Q3 2023 reduction was Ocular Therapeutix, cutting an estimated $817K.
  • Knoll Capital Management fully exited Altimmune in Q3 2023, selling an estimated $614K.
  • Knoll Capital Management's ten largest holdings make up 71% of its $96.3M portfolio in Q3 2023.
  • Knoll Capital Management opened 12 new positions and closed 2 in Q3 2023.
  • Knoll Capital Management's portfolio value rose 17% quarter-over-quarter to $96.3M.

Based on Knoll Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.